Literature DB >> 31256283

Arylboronic acids inhibit P2X7 receptor function and the acute inflammatory response.

Robson Xavier Faria1,2, Noemi de Jesus Hiller3, Juliana Pimenta Salles4, Jackson Antonio Lamounier Camargos Resende5, Roberta Tosta Diogo4,6, Natalia Lidmar von Ranke6,7, Murilo Lamim Bello7, Carlos Rangel Rodrigues7, Helena Carla Castro6, Daniela de Luna Martins3.   

Abstract

The P2X7 receptor (P2X7R) is an ion channel which is activated by interactions with the extracellular ATP molecules. The molecular complex P2X7R/ATP induces conformational changes in the protein subunits, opening a pore in the ion channel macromolecular structure. Currently, the P2X7R has been studied as a potential therapeutic target of anti-inflammatory drugs. Based on this, a series of eight boronic acids (NO) analogs were evaluated on the biologic effect of this pharmacophoric group on the human and murine P2X7R. The boronic acids derivatives NO-01 and NO-12 inhibited in vitro human and murine P2X7R function. These analogs compounds showed effect better than compound BBG and similar to inhibitor A740003 for inhibiting dye uptake, in vitro IL-1β release and ATP-induced paw edema in vivo. In both, in vitro and in vivo assays the compound NO-01 showed to be the hit compound in the present series of the arylboronic acids analogs. The molecular docking suggests that the NO derivatives bind into the upper body domain of the P2X7 pore and that the main intermolecular interaction with the two most active NO derivatives occur with the residues Phe 95, 103 and 293 by hydrophobic interactions and with Leu97, Gln98 and Ser101 by hydrogen bonds.. These results indicate that the boronic acid derivative NO-01 shows the lead compound characteristics to be used as a scaffold structure to the development of new P2X7R inhibitors with anti-inflammatory action.

Entities:  

Keywords:  Boronic acids; Dye uptake; IL-1β release; Molecular docking; P2X7R; Paw edema

Mesh:

Substances:

Year:  2019        PMID: 31256283     DOI: 10.1007/s10863-019-09802-x

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  57 in total

1.  Proteomic and functional evidence for a P2X7 receptor signalling complex.

Authors:  M Kim; L H Jiang; H L Wilson; R A North; A Surprenant
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

2.  X-ray crystallographic study of boronic acid adducts with subtilisin BPN' (Novo). A model for the catalytic transition state.

Authors:  D A Matthews; R A Alden; J J Birktoft; S T Freer; J Kraut
Journal:  J Biol Chem       Date:  1975-09-25       Impact factor: 5.157

3.  RM1: a reparameterization of AM1 for H, C, N, O, P, S, F, Cl, Br, and I.

Authors:  Gerd B Rocha; Ricardo O Freire; Alfredo M Simas; James J P Stewart
Journal:  J Comput Chem       Date:  2006-07-30       Impact factor: 3.376

4.  Anticancer activities of novel chalcone and bis-chalcone derivatives.

Authors:  Aneta Modzelewska; Catherine Pettit; Geetha Achanta; Nancy E Davidson; Peng Huang; Saeed R Khan
Journal:  Bioorg Med Chem       Date:  2006-01-24       Impact factor: 3.641

Review 5.  Boron therapeutics on the horizon.

Authors:  M P Groziak
Journal:  Am J Ther       Date:  2001 Sep-Oct       Impact factor: 2.688

6.  A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages.

Authors:  Anne N Shemon; Ronald Sluyter; Suran L Fernando; Alison L Clarke; Lan-Phuong Dao-Ung; Kristen K Skarratt; Bernadette M Saunders; Khai See Tan; Ben J Gu; Stephen J Fuller; Warwick J Britton; Steven Petrou; James S Wiley
Journal:  J Biol Chem       Date:  2005-11-01       Impact factor: 5.157

7.  Brilliant blue G selectively blocks ATP-gated rat P2X(7) receptors.

Authors:  L H Jiang; A B Mackenzie; R A North; A Surprenant
Journal:  Mol Pharmacol       Date:  2000-07       Impact factor: 4.436

8.  Design, synthesis, and biological evaluation of aminoboronic acids as growth-factor receptor inhibitors of EGFR and VEGFR-1 tyrosine kinases.

Authors:  Toru Asano; Hiroyuki Nakamura; Yoshimasa Uehara; Yoshinori Yamamoto
Journal:  Chembiochem       Date:  2004-04-02       Impact factor: 3.164

9.  Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents.

Authors:  Srinivas K Kumar; Erin Hager; Catherine Pettit; Hallur Gurulingappa; Nancy E Davidson; Saeed R Khan
Journal:  J Med Chem       Date:  2003-07-03       Impact factor: 7.446

Review 10.  Molecular physiology of P2X receptors.

Authors:  R Alan North
Journal:  Physiol Rev       Date:  2002-10       Impact factor: 37.312

View more
  2 in total

1.  Eugenia sulcata (Myrtaceae) Nanoemulsion Enhances the Inhibitory Activity of the Essential Oil on P2X7R and Inflammatory Response In Vivo.

Authors:  Bettina Quintanilha Magalhães; Francisco P Machado; Paola S Sanches; Bárbara Lima; Deborah Quintanilha Falcão; Natalia von Ranke; Murilo Lamim Bello; Carlos Rangel Rodrigues; Marcelo Guerra Santos; Leandro Rocha; Robson X Faria
Journal:  Pharmaceutics       Date:  2022-04-21       Impact factor: 6.525

Review 2.  The Boron Advantage: The Evolution and Diversification of Boron's Applications in Medicinal Chemistry.

Authors:  Katia Messner; Billy Vuong; Geoffrey K Tranmer
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.